Acknowledgements
The authors would like to acknowledge the contributions of all the members of the Social Drivers Advisory Group, whose insights and inputs contributed vitally to the views and findings presented here. Thanks are due to all authors for their hard work conceptualising and writing the papers herein, as well as all workshop and community conversation participants for their perspectives. Special thanks to Judy Auerbach for contributing to the historical context section of this editorial.
Notes
1. Factors at a relatively far remove from the actual site of transmission.
2. For example, see Centers for Disease Control and Prevention – ‘The Social-Ecological Model for Violence Prevention’. Available from: http://www.cdc.gov/ncipc/dvp/Social-Ecological-Model_DVP.htm.
3. Many thanks to Judy Auerbach for pointing out this short evolution in HIV prevention frames.
4. In 2010 the CAPRISA 004 tenofovir trials showed that this gel – applied vaginally 12 hours before and within 12 hours after sexual intercourse – reduced HIV incidence in trial participants (sexually active South African women between the ages of 18 and 40 years) by 39%. Later the same year the iPrEx trial results showed that in gay men, transgender women and other men who have sex with men, a combination drug taken before sex could reduce the risk of HIV by 44%. Studies are ongoing in other populations.